Aura Biosciences Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
AURA$7.66+16.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $26,279 | $41,063 |
| Marketable securities | 176,595 | 185,087 |
| Restricted cash and deposits | — | 19 |
| Prepaid expenses and other current assets | 9,375 | 5,625 |
| Total current assets | 212,249 | 231,794 |
| Restricted cash and deposits, net of current portion | 768 | 768 |
| Right of use assets - operating lease | 18,501 | 18,854 |
| Other long-term assets | 453 | 509 |
| Property and equipment, net | 3,054 | 3,150 |
| Total Assets | $235,025 | $255,075 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | 1,933 | 1,787 |
| Short-term operating lease liability | 2,741 | 2,687 |
| Accrued expenses and other current liabilities | 4,989 | 7,883 |
| Total current liabilities | 9,663 | 12,357 |
| Long-term operating lease liability | 16,579 | 16,870 |
| Total Liabilities | 26,242 | 29,227 |
| Commitments and Contingencies (Note 12) | ||
| Stockholders’ Equity: | ||
| Common stock, $0.00001 par value, 150,000,000 authorized at March 31, 2024 and December 31, 2023, and 49,504,405 and 49,350,788 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | — | — |
| Additional paid-in capital | 515,779 | 512,617 |
| Accumulated deficit | (307,014) | (287,308) |
| Accumulated other comprehensive loss | 18 | 539 |
| Total Stockholders’ Equity | 208,783 | 225,848 |
| Total Liabilities and Stockholders’ Equity | $235,025 | $255,075 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.